Clinical Trial Update: Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on a Phase 1/2 study evaluating the combination of durvalumab, tremelimumab, and selumetinib in patients with recurrent or stage IV non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Selumetinib (selumetinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1, Phase 2 | Status: COMPLETED